TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06521411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CSA model
Description: Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided in subsidized weekly boxes for 20 weeks to community members at Brooklyn Grange Farm in Sunset Park at a fee of $5, which was determined to be acceptable by community members. Participants that receive SNAP benefits can use their EBT card to cover their $5. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
Study: NCT05212675

Intervention type: OTHER
Group type: OTHER
Intervention: Short daily dialysis
Description: 7 days 2hours dialysis
Study: NCT04743310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tozuleristide
Description: tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canvas imaging system
Description: imaging device attached to surgical microscope
Study: NCT05083078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab will be administered subcutaneously.
Study: NCT04743310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of tumor
Description: Standard of care surgical resection of tumor
Study: NCT05195775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (Doppler US, exercise testing, clinical function) will be performed 3 hours after time of dosing.
Study: NCT05036408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Participate in group psychological intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend educational session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulative and Body-Based Intervention Procedure
Description: Undergo osteopathic manual treatments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Participate in occupational therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participate in physical activity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Participate in physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05339113

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET/CT
Description: Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
Study: NCT06557655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeinate chewing gum
Description: participants either chewed caffeinated gum (CAF) containing 3 mg/kg caffeine or a caffeine-free placebo gum (PLA) for 10 minutes prior to undertaking a series of tests on-ice and off-ice.
Study: NCT04919720

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FRAM Model and Human Factors/Quality Improvement Intervention
Description: The group will use semi-structured interviews and ethnographic observations to inform development of a Functional Resonance Analysis Method (FRAM) model of the process for rescue of deteriorating patients in EGS, using information from 3 hospitals. A focus group approach will be used in co-designing reform of the system for responding to post-operative deterioration, working with small groups of frontline clinical staff from relevant areas in the three Trusts involved.
Study: NCT03734952

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy program
Description: A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
Study: NCT05912712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment
Description: 10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
Study: NCT05210244

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (BJ) acute supplementation
Description: One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice (PLA) acute supplementation
Description: One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
Study: NCT05780021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Support Program Emotiv
Description: A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
Study: NCT04805918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VIPP-SD
Description: Parenting program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIPP-SD
Description: Parenting program
Study: NCT05857566

Intervention type: DRUG
Group type: OTHER
Intervention: RDX-002
Description: A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
Study: NCT05912712

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment
Description: 10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
Study: NCT05857566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX-002
Description: A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
Study: NCT05912712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine Suppository Treatment
Description: For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
Study: NCT06557655

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffeinate chewing gum
Description: participants either chewed caffeinated gum (CAF) containing 3 mg/kg caffeine or a caffeine-free placebo gum (PLA) for 10 minutes prior to undertaking a series of tests on-ice and off-ice.
Study: NCT04985084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention group
Description: The intervention will last for four weeks and target six dietary behaviors related to gastric cancer. The intervention components include one session of face-to-face education prior to discharge and three sessions of telephone counselling after discharge. The face-to-face education will last for 20 to 30 minutes and each session of telephone counselling will last for 10 to 20 minutes. All the interventional sessions are individual based.
Study: NCT06188338

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.
Description: Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®
Description: Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
Study: NCT05912712

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab Treatment
Description: Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Infliximab Treatment
Description: Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab Treatment
Description: Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
Study: NCT04985084

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: General dietary advice provided as routine by the ward nurses before discharge from the hospital.
Study: NCT05545904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance use brief intervention (BI)
Description: The BI will be delivered in a single session (20-30 minutes) using motivational interviewing techniques and the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
Study: NCT05245539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231
Description: CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231
Description: CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
Study: NCT05545904

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: substance use education intervention
Description: This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
Study: NCT05200156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidyl Choline
Description: conventional management + phosphatidyl choline tablets
Study: NCT04736329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
Study: NCT05491044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orelabrutinib
Description: Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
Study: NCT04869670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric peroral endoscopic myotomy.
Description: Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Gastric peroral endoscopic myotomy.
Description: Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind.
Study: NCT06199622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: 20 minutes of classical Turkish musicor classical western music
Study: NCT06216587

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BLa80
Description: Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BLa80.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BLa80
Description: Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BLa80.
Study: NCT06315205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole LEBE 75 mg
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole LEBE 150 mg
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole LEBE 225 mg
Description: 14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
Study: NCT04908241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAIL
Description: Each week has a specific focus for lower extremity rehabilitation:~Week 1) Building a base: 8 exercises, 10-15 repetitions x 2-3 sets~Week 2) Increasing repetitions: 8 exercises, 15-20 repetitions x 3 sets~Week 3) Building exercise tolerance:10 exercises, 15-20 repetitions x 3 sets~Week 4) Maximizing repetitions: 10 exercises, 30 seconds as many reps as possible x 2 sets~At the end of the second exercise session each week, the therapist and participants work collaboratively to develop an independent exercise action plan to be completed before the first session of the next week. The self-managed plans includes exercises selected from TRAIL, agreed upon by the participant and therapist, that are safe to perform without therapist oversight. The aims of the exercise action plan are to: i) Add exercise volume without using program resources (e.g., therapist time); and ii) Build capacity for self-management for long-term health and well-being after TRAIL has ended.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDUCATION
Description: EDUCATION has a specific focus on:~Week 1) What is stroke (e.g., gaining an understanding of the function of the brain, types of stroke and how stroke affects physical function) and introduction to self-management;~Week 2) What is self-management;~Week 3) Self-management for post-stroke complications (e.g., activities of daily living);~Week 4) Self-management for secondary prevention (e.g., blood pressure, diet, medication, stress management).~Education therapists will be provided with lesson plans and manuals to be circulated with the participants, and will facilitate the educational session through interactive Powerpoint presentations. In addition, participants will be asked to complete 30-60 minutes of educational homework, which will be discussed at the commencement of the following session.
Study: NCT05363670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARS-1
Description: ARS-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARS-1
Description: ARS-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol MDI
Description: 180 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05783895

Intervention type: DIAGNOSTIC_TEST
Intervention: Post screening diagnostic test
Description: 1) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.

Intervention type: DIAGNOSTIC_TEST
Intervention: Post screening diagnostic test
Description: 1) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.
Study: NCT05524831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KINESIOTAPE
Description: kinesiotape will be applied on orbicularis oris muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oromotor training
Description: selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
Study: NCT06251414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Blood Flow Restriction (BFR) training, also known as occlusion training or restricted blood flow training, involves applying external pressure to a limb using inflatable cuffs or elastic bands. This pressure partially restricts arterial blood flow while occluding venous blood flow in the pressured limb. The goal is to increase muscle strength and size by creating metabolic stress and promoting physiological adaptations, such as muscle hypertrophy, with lighter loads than traditional resistance training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrument-Assisted Soft Tissue Mobilization
Description: Instrument-Assisted Soft Tissue Mobilization (IASTM) is a therapeutic technique that involves the use of specially designed tools or instruments to apply controlled mechanical pressure to soft tissues in the body. These tools are typically made of stainless steel or other materials and have various shapes and edges. The primary aim of IASTM is to address musculoskeletal conditions by breaking down scar tissue, fascial restrictions, and adhesions in the soft tissues. Practitioners use the instruments to detect and treat areas of tissue dysfunction, promoting improved range of motion, reduced pain, and enhanced functional mobility.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Tuinal
Description: Tuinal, also known as Tui Na or Chinese therapeutic massage, is a traditional Chinese medicine (TCM) healing technique that involves manual manipulation of the body's soft tissues, including muscles and tendons. It is a form of bodywork that aims to balance the flow of vital energy (Qi) within the body and promote overall well-being. Tuina techniques may include kneading, rolling, pressing, and brushing, and they are applied to specific acupressure points or along the body's meridians. Tuina is used to address various health concerns, alleviate pain, improve circulation, and enhance the body's natural healing processes, making it an integral part of traditional Chinese medicine.
Study: NCT04941105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: A single subcutaneous administration of 140 mg evolocumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: A single subcutaneous injection of 1ml of 0,9% saline solution
Study: NCT06175780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY-0118
Description: KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY-0118
Description: KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY-0118
Description: KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
Study: NCT06036888

Intervention type: OTHER
Intervention: questionaries completion
Description: Answer to the DASH and SF-12 questionaries, for an estimated duration of 15 minutes.
Study: NCT05270200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Patients will recieve six courses of azacitidine 100mg through a needle under skin on Days 1-5.Each course is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Patients will recieve oral chidamide 5mg per day for no more than 2 years.
Study: NCT05983913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-motor training
Description: The cognitive-motor training program consists of five cognitive tasks related to concentration, reaction time, and executive function, combined with physical exercises using an interactive system. The five tasks include: (1) number sequence, (2) number-word sequence, (3) card matching games, (4) memorizing numbers, and (5) route-finding games.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognition training
Description: The intervention consists of five cognitive tasks (memory, attention, spatial and temporal perception) with difficulty levels adapted to the individual's cognitive abilities.